EGFR and neoplasm: For EGFR Mut LUAD patients, the emergence of drug-resistant EGFR mutations through tumor evolution and selective pressure from therapeutic interventions underscores the critical need for novel EGFR-targeting agents with alternative inhibitory mechanisms.